Our Products
Loans
Cards
Insurance
Investment
Stock Market
Electronics Mall
CIBIL Score
Knowledge Centre
Academy 
Calculators
Our Services
Cibil Report
Get cibil report
My Account
Log In
Log into your account
Offers
Check out pre-approved offers now!
Languages
Chosen Language: English
Do Not Call
Do not call
En
Medicamen Organics Ltd. Share Price
N/A
1D
1M
3M
6M
1Y
5Y
Day's Range
Day's Range
Low
₹26.00
High
₹26.00
Price Summary
| Previous Close | ₹26.00 |
|---|---|
| Day's Range | ₹26.00 - ₹26.00 |
| Open | ₹26.00 |
| 52 Week Range | ₹20.05 - ₹49.70 |
| Volume | 4,000 |
| Market Cap | ₹0.00 |
Stocks Summary
| Trade Value ( ₹ in Lacs) | 1.04 |
|---|---|
| Market Cap (₹ in Mn) | 0.00 |
| Dividend Yield(%) | 0.00 |
| Price/Earning (TTM) | 7.52 |
| TTM EPS (₹) | 3.46 |
| P/E Ratio | 6.27 |
| Book Value(₹) | 1.04 |
| PAT Margin (%) | 10.60 |
| Face Value (₹) | 10.00 |
| ROCE(%) | 16.97 |
Financials
| Particulars | QTR FY (₹ in Millions) | Annual FY (₹ in Millions) |
|---|---|---|
| Net sales | N/A | 252.72 |
| Expenses | N/A | N/A |
| PBT | N/A | 44.37 |
| Operating profit | N/A | 0.0 |
| Net profit | N/A | 26.24 |
About Medicamen Organics Ltd.
| Founded | 1995 |
|---|---|
| Managing Director | Bal Kishan Gupta |
| NSE Symbol | MEDIORG |
Peer Comparision
| Stocks Name | Market Cap (Cr)(₹) | Market Price (₹) | 52 Week Low-High (₹) |
|---|---|---|---|
| Sun Pharmaceutical Industries Ltd. | 4,37,734.67 | 1,863.00 | 1,548.00 - 1,548.00 |
| Divi's Laboratories Ltd. | 1,80,311.57 | 6,947.00 | 5,636.50 - 5,636.50 |
| Torrent Pharmaceuticals Ltd. | 1,45,369.09 | 4,417.65 | 3,102.00 - 3,102.00 |
| Apollo Hospitals Enterprise Ltd. | 1,15,044.98 | 8,113.50 | 6,696.50 - 6,696.50 |
| Cipla Ltd. | 1,07,204.87 | 1,434.00 | 1,165.70 - 1,165.70 |
| Dr. Reddy's Laboratories Ltd. | 1,05,592.45 | 1,302.80 | 1,148.40 - 1,148.40 |
| Lupin Ltd. | 1,01,293.89 | 2,255.00 | 1,836.80 - 1,836.80 |
| Max Healthcare Institute Ltd. | 99,791.55 | 1,052.50 | 903.00 - 903.00 |
| Mankind Pharma Ltd. | 99,384.29 | 2,457.60 | 1,909.70 - 1,909.70 |
| Zydus Lifesciences Ltd. | 94,480.34 | 991.30 | 835.50 - 835.50 |
No Records Found
Latest News
May
14
2026
Posted on May 14th 2026
Caplin Point Laboratories informs about outcome of board meeting
Further to intimation dated May 07, 2026, Caplin Point Laboratories has informed that the Board of Directors, at its meeting held today, has declared an Interim Dividend of Rs 4.00 (200%) per equity share of face value of Rs 2 each for the financial year ended March 31, 2026; fixed May 30, 2026 as Record Date for determining the eligibility of the Shareholders for the purpose of Interim Dividend; approved the Audited standalone and consolidated financial results (including segment reporting for the consolidated results) of the Company for the year ended March 31, 2026, along with Auditors Report (Annexure-1). They also enclosed a Press Release issued by the Company (Annexure-2) and an investor presentation in this regard (Annexure-3); approved amendments to Code of Practices and Procedure for Fair Disclosure of Unpublished Price Sensitive Information. The aforesaid code has been made available on the website of the Company at https://www.caplinpoint.net/index.php/corporate-governance/ They are also enclosing the information w.r.t. Large Corporate as Annexure -4. They confirmed and declared that the Statutory Auditors of the Company i.e., Brahmayya & Co, Chartered Accountants, have issued the audit report on Standalone and Consolidated Financial Statements of the Company for the year ended March 31, 2026, with unmodified opinion. The meeting commenced at 11.10 AM and concluded at 1.10 PM.
The above information is a part of company’s filings submitted to BSE.
Read More
May
14
2026
Posted on May 14th 2026
Shilpa Medicare submits analyst meet intimation
Pursuant to Regulation 30(2) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, Shilpa Medicare has enclosed the schedule of Q4- FY26 Earnings Conference Call, which is to be held on Friday, May 22, 2025, at 16.00 hrs. A copy of this intimation is also being made available at: https://www.vbshilpa.com/investor-presentation.php
The above information is a part of company’s filings submitted to BSE.
Read More
May
14
2026
Posted on May 14th 2026
Kaya informs about board meeting
Kaya has informed that the meeting of the Board of Directors of the Company is scheduled to be held on May 20, 2026, to consider and approve the Audited Consolidated and Standalone financial results of the Company for the quarter and financial year ended March 31, 2026; and take on record the Auditors' Report on Standalone and Consolidated Financial results. The trading window for dealing in the Company's shares has been closed from April 01, 2026 till May 22, 2026.
The above information is a part of company’s filings submitted to BSE.
Read More
May
14
2026
Posted on May 14th 2026
Alembic Pharmaceuticals informs about press release
Alembic Pharmaceuticals has informed that the Company has received US Food & Drug Administration (USFDA) Tentative Approval for Darolutamide Tablets, 300 mg. The company has enclosed a press release in this regard.
The above information is a part of company’s filings submitted to BSE.
Read More
May
14
2026
Posted on May 14th 2026
Glaxosmithkline Phar - Quaterly Results
With no major difference for the quarter endedMarch 2026 , the total revenue stood at Rs. 9891.50 millions.Net profit stood at Rs. 2749.40 millions compared to Rs. 2601.40 millions in the corresponding previous quarter,high by 5.69%.Operating profit for the quarter ended March 2026 rose to 3829.00 millions as compared to 3702.00 millions of corresponding quarter ended March 2025.
| (Rs. in Million) |
| Quarter ended | Year to Date | Year ended | |||||||
| 202603 | 202503 | % Var | 202603 | 202503 | % Var | 202603 | 202503 | % Var | |
| Sales | 9891.50 | 9660.80 | 2.39 | 37902.00 | 37234.90 | 1.79 | 37902.00 | 37234.90 | 1.79 |
| Other Income | 357.10 | 394.60 | -9.50 | 1425.60 | 1425.60 | 0.00 | 1425.60 | 1425.60 | 0.00 |
| PBIDT | 3829.00 | 3702.00 | 3.43 | 14427.60 | 13118.50 | 9.98 | 14427.60 | 13118.50 | 9.98 |
| Interest | 6.10 | 5.80 | 5.17 | 27.30 | 13.10 | 108.40 | 27.30 | 13.10 | 108.40 |
| PBDT | 3822.90 | 3696.20 | 3.43 | 14426.70 | 13152.30 | 9.69 | 14426.70 | 13152.30 | 9.69 |
| Depreciation | 131.70 | 147.20 | -10.53 | 664.40 | 667.90 | -0.52 | 664.40 | 667.90 | -0.52 |
| PBT | 3691.20 | 3549.00 | 4.01 | 13762.30 | 12484.40 | 10.24 | 13762.30 | 12484.40 | 10.24 |
| TAX | 941.80 | 947.60 | -0.61 | 3644.10 | 3293.80 | 10.64 | 3644.10 | 3293.80 | 10.64 |
| Deferred Tax | 69.40 | 54.20 | 28.04 | 94.60 | 62.00 | 52.58 | 94.60 | 62.00 | 52.58 |
| PAT | 2749.40 | 2601.40 | 5.69 | 10118.20 | 9190.60 | 10.09 | 10118.20 | 9190.60 | 10.09 |
| Equity | 1694.10 | 1694.10 | 0.00 | 1694.10 | 1694.10 | 0.00 | 1694.10 | 1694.10 | 0.00 |
| PBIDTM(%) | 38.71 | 38.32 | 1.02 | 38.07 | 35.23 | 8.04 | 38.07 | 35.23 | 8.04 |
Read More
No Records Found
Sign in to Unlock Offers!
We don't SPAM
Frequently Asked Questions
The current share price of Medicamen Organics Ltd. is ₹26.00 as of 2026-05-14.
The market capitalisation of Medicamen Organics Ltd. is ₹30.42 as of 2026-05-13.
The 1-year return of Medicamen Organics Ltd. is 0.00% as of 2026-05-14.
The P/E ratio of Medicamen Organics Ltd. is 6.27 as of 2026-05-14.
The 52-week high and low of Medicamen Organics Ltd. are ₹49.70 and ₹20.05, respectively, as of 2026-05-14.
View More
Disclaimer
All content and research information displayed on the Site, are obtained from our partner Accord Fintech Private Limited. an authorized data feed vendor of BSE/NSE/MCX/NCDEX exchange. The data is provided on ‘As-Is’ basis and is not a live data feed but a feed with 15 minutes delay or more. Bajaj Markets does not warrant accuracy, completeness, timely availability of the information and data available on the Site. Past performance, when presented, is purely for reference purposes and is not a guarantee of similar future results.
The Services offered on the Site does not constitute investment advice in any manner whatsoever. You shall be solely responsible for any investment decisions made by placing reliance on the information provided on the Site.
Bajaj Markets partners with financial services entities for sourcing leads for services such as DEMAT accounts etc. In case you wish to avail the services, you shall be redirected to partners platform and shall be bound by the terms and conditions, privacy policy governing the said platform.
Home
Shopping
Loan Offers
My Accounts
Explore
